We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
-22.83%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$220M
AUM Growth
-$32.4M
Cap. Flow
-$637K
Cap. Flow %
-0.29%
Top 10 Hldgs %
98.43%
Holding
15
New
10
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$4.37M
2
BABA icon
Alibaba
BABA
+$4.22M
3
NKTR icon
Nektar Therapeutics
NKTR
+$3.33M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$3.21M
5
OPK icon
Opko Health
OPK
+$3.2M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 85.52%
2 Consumer Discretionary 2.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
1
Heron Therapeutics
HRTX
$86.3M
$98.6M 44.89%
5,190,837
– –
LJPC
2
DELISTED
La Jolla Pharmaceutical Company
LJPC
$63.8M 29.06%
3,052,130
+180,000
+6% +$3.21M
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$11.5B
$7.44M 3.39%
90,215
– –
SRPT icon
4
Sarepta Therapeutics
SRPT
$1.66B
$4.88M 2.22%
+250,000
New +$4.37M
BABA icon
5
Alibaba
BABA
$269B
$4.74M 2.16%
+60,000
New +$4.22M
OPK icon
6
Opko Health
OPK
$921M
$3.64M 1.66%
+350,000
New +$3.2M
NKTR icon
7
Nektar Therapeutics
NKTR
$2.39B
$3.58M 1.63%
+17,333
New +$3.33M
INFI
8
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$2.42M 1.1%
+460,000
New +$2.82M
BCRX icon
9
BioCryst Pharmaceuticals
BCRX
$2.37B
$1.22M 0.55%
+430,000
New +$1.91M
LPCN icon
10
Lipocine
LPCN
$17.1M
$1.01M 0.46%
+5,882
New +$1M
ATYR
11
aTyr Pharma
ATYR
$46.4M
$749K 0.34%
+13,571
New +$1.03M
RXDX
12
DELISTED
Ignyta, Inc.
RXDX
$271K 0.12%
+40,000
New +$329K
CLDX icon
13
Celldex Therapeutics
CLDX
$2.77B
$189K 0.09%
+3,333
New +$375K

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $1.98B AUM 1.62% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return

Tang Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, Tang Capital Management held 15 positions worth $220M, down 13% from $252M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Tang Capital Management's Q1 2016 filing shows 10 new and 1 increased positions. Its largest new stake was Sarepta Therapeutics: 250,000 shares worth $4.88M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 90% a quarter earlier, followed by Consumer Discretionary.

  • Tang Capital Management's largest Q1 2016 buy was Sarepta Therapeutics: 250,000 shares worth $4.88M.
  • Tang Capital Management added most to La Jolla Pharmaceutical Company in Q1 2016, an estimated $3.21M increase.
  • Tang Capital Management's ten largest holdings make up 98% of its $220M portfolio in Q1 2016.
  • Tang Capital Management opened 10 new positions and closed 0 in Q1 2016.
  • Tang Capital Management's portfolio value fell 13% quarter-over-quarter to $220M.

Based on Tang Capital Management's 13F filing for Q1 2016, filed 16 May 2016.